Privia Health Group, Inc.
PRVAHealthcareNASDAQHealth Information Services · Last scanned Oct 26, 2026
Scan Results
Daily timeframePrivia Health Group, Inc. operates as a national physician-enablement company in the United States. The company carries a $2.86B market cap, placing it firmly in the mid-cap category. The company collaborates with physician practices, health plans, and health systems.
Market Cap
$2.86B
Beta
0.80
P/E (TTM)
106.71
P/E (Fwd)
21.08
EPS (TTM)
$0.21
EPS (Fwd)
$1.06
ROE
4.3%
ROA
2.0%
Cash
$412.2M
Total Debt
$8.7M
Free CF
$95.6M
52W Change
-12.9%
Annual Financials
Cash vs Debt
Where PRVA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PRVA finished 1.01% below its 150-day moving average ($22.67) and 1.28% below its 200-day moving average ($22.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRVA overbought or oversold?
At the October 20, 2026 close, PRVA's RSI(14) was 87.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $412.2M in cash comfortably exceeding the $8.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $95.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 4.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.36B (2022) to $2.12B (2025), reflecting a 56% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, PRVA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing PRVA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.